Study of Tiragolumab and Atezolizumab in Patients With SMARCB1- or SMARCA4-Deficient Tumors

Phase: Recruiting

Condition(s): Atypical Teratoid Rhabdoid Tumor, Chordoma, Epithelioid Sarcoma, Malignant Rhabdoid Tumor, Renal Medullary Carcinoma

NCT Number: NCT05286801 Other Study ID Number(s): PEPN2121

What Is the Purpose of This Study?

This trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory).

Who Can Take Part in This Study?

People who may be eligible for this study:

  • Patients must be >= 12 months and have SMARCB1 (INI1) or SMARCA4 deficient tumors.
  • Patients must have relapsed, refractory disease or newly diagnosed disease for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life.
For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT05286801

What Will Happen During This Study?

  • Patients receive atezolizumab IV over 30-60 minutes on day 1 and tiragolumab IV over 30-90 minutes on day 1 of each cycle.
  • OR receive tiragolumab IV over 30-90 minutes on day 1 of each cycle and atezolizumab IV over 30-60 minutes on day 1 of each cycle starting in cycle 2.
  • Treatment repeats every 21 days for up to 5 years.

Principal Investigator

Bhuvana A. Setty
MD

Hematology & Oncology

Discover More Research
Explore additional studies relating to sarcoma and solid tumors